9rules - The best content from the independent web.

Browse 9rules By - Great blogs sorted by topic at 9rules.

Pharma Strategy Blog By Sally Church

Member Since 2009 of the Science Community

Recent Posts

Making a difference in pancreatic cancer – an interview with Dr Hedy Lee Kindler »

Posted Feb 12, 2013

Will ASCO GI herald a new era for pancreatic cancer? »

Posted Jan 24, 2013

Effectively targeting KRAS in lung cancer with a MEK inhibitor »

Posted Nov 29, 2012

Time to rethink cancer clinical trials strategy? »

Posted Nov 27, 2012

Zaltrap – a simple dosing error or not? »

Posted Nov 09, 2012

Update on KRAS in pancreatic cancer »

Posted Oct 12, 2012

Prospect of Abraxane in Pancreatic Cancer excites ESMO 2012 »

Posted Sep 30, 2012

Update on bavituximab in non-squamous lung cancer »

Posted Sep 11, 2012

ASCO 2012 Update 2: Overcoming resistance in metastatic melanoma »

Posted Jun 29, 2012

A surfeit of riches in CLL and NHL: on bruton kinase and PI3K delta inhibitors »

Posted Jun 27, 2012

ASCO 2012 Update 1: Advanced Lung Cancer »

Posted Jun 26, 2012

Interested in the PI3K-AKT-mTOR pathway in cancer research? »

Posted Jun 20, 2012

Aggregating the 2012 ASCO tweets »

Posted Jun 01, 2012

Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone »

Posted May 25, 2012

Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases »

Posted May 22, 2012

Reflections of a Medical Oncologist on AACR 2012 »

Posted May 18, 2012

ASCO 2012 Preview – Highlights of key data emerging from Chicago »

Posted May 15, 2012

ASCO 2012 Acronym Mania! »

Posted May 14, 2012

Ribonucleases (RNase) – clinical applications for cancer therapy »

Posted May 01, 2012

Ribonucleases (RNase) what are they and why are they relevant to cancer? »

Posted Apr 30, 2012